NI201000042A - Anticuerpos anti-il-12/23p40, epitopes, formulaciones, composiciones, métodos y usos. - Google Patents

Anticuerpos anti-il-12/23p40, epitopes, formulaciones, composiciones, métodos y usos.

Info

Publication number
NI201000042A
NI201000042A NI201000042A NI201000042A NI201000042A NI 201000042 A NI201000042 A NI 201000042A NI 201000042 A NI201000042 A NI 201000042A NI 201000042 A NI201000042 A NI 201000042A NI 201000042 A NI201000042 A NI 201000042A
Authority
NI
Nicaragua
Prior art keywords
formulations
methods
compositions
epitopes
antibodies
Prior art date
Application number
NI201000042A
Other languages
English (en)
Inventor
Dal Monte Paul
Giles-Komar Jill
Heavner George
Knight David
Khossravi Mehrnaz
Luo Jeffrey
Shealy David
Volkin David
Original Assignee
Centocor Ortho Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Ortho Biotech Inc filed Critical Centocor Ortho Biotech Inc
Publication of NI201000042A publication Critical patent/NI201000042A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un anticuerpo anti-IL-12/23p40 que se une a una porción de la proteína de IL-12 o IL-23 que corresponde a la subunidad p40 de IL-12 o IL-23, incluyendo composiciones, formulaciones y métodos de administración que tienen aplicaciones en usos y dispositivos de diagnósticos y/o terapéuticos.
NI201000042A 2007-09-28 2010-03-25 Anticuerpos anti-il-12/23p40, epitopes, formulaciones, composiciones, métodos y usos. NI201000042A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97599707P 2007-09-28 2007-09-28

Publications (1)

Publication Number Publication Date
NI201000042A true NI201000042A (es) 2010-09-13

Family

ID=40850818

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201000042A NI201000042A (es) 2007-09-28 2010-03-25 Anticuerpos anti-il-12/23p40, epitopes, formulaciones, composiciones, métodos y usos.

Country Status (9)

Country Link
US (1) US20090181027A1 (es)
EP (1) EP2205276A4 (es)
CR (1) CR11399A (es)
EC (1) ECSP10010056A (es)
GT (1) GT201000073A (es)
HN (1) HN2010000573A (es)
NI (1) NI201000042A (es)
SV (1) SV2010003517A (es)
WO (1) WO2009114040A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2821926A1 (en) * 2011-01-07 2012-07-12 Abbvie Inc. Anti-il-12/il-23 antibodies and uses thereof
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
JP2020500152A (ja) * 2016-09-30 2020-01-09 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬を治療する安全かつ有効な方法
WO2018181876A1 (ja) 2017-03-31 2018-10-04 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 水性製剤及び注射器入り水性製剤、並びに、抗体タンパク脱凝集剤及び抗体タンパク脱凝集方法
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
MX2019013072A (es) 2017-05-02 2019-12-16 Merck Sharp & Dohme Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019106206A1 (en) * 2017-12-01 2019-06-06 Fyb 202 Project Gmbh Stable, low viscosity, high concentration liquid formulations of an anti-il-12/23p40 antibody
US11578124B2 (en) 2018-05-18 2023-02-14 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-IL12/IL23 antibody
MD3883606T3 (ro) 2018-09-24 2024-03-31 Janssen Biotech Inc Metodă sigură și eficientă de tratament al colitei ulcerative cu anticorpi anti-IL12/IL23
KR20210093973A (ko) 2018-11-20 2021-07-28 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법
KR20220012883A (ko) 2019-05-23 2022-02-04 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용요법으로 염증성 장질환을 치료하는 방법
KR20220038775A (ko) * 2019-07-30 2022-03-29 아케소 바이오파마, 인크. 항-인간 p40 단백질 도메인 항체 및 이의 용도
EP4103606A4 (en) * 2020-02-14 2024-04-10 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD FOR TREATING ULCERATIVE COLITIS WITH ANTI-IL-12/IL23 ANTIBODIES

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
TR200802278T2 (tr) * 1999-03-25 2008-08-21 Abbott Gmbh & Co. Kg Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler.
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
JP5485489B2 (ja) * 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
MY157915A (en) * 2004-12-21 2016-08-15 Centocor Inc Anti-il-12 antibodies, epitopes, compositions, methods and uses.
AU2006220829C1 (en) * 2005-03-08 2024-02-01 Pfizer Products Inc. Anti-CTLA-4 antibody compositions
US20060286103A1 (en) * 2005-06-15 2006-12-21 Parag Kolhe Stable antibody formulation
AU2006261920A1 (en) * 2005-06-23 2007-01-04 Medimmune, Llc Antibody formulations having optimized aggregation and fragmentation profiles
WO2007074880A1 (ja) * 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤

Also Published As

Publication number Publication date
EP2205276A2 (en) 2010-07-14
GT201000073A (es) 2012-04-19
ECSP10010056A (es) 2010-04-30
EP2205276A4 (en) 2012-08-15
HN2010000573A (es) 2012-12-10
SV2010003517A (es) 2010-08-10
CR11399A (es) 2010-08-18
US20090181027A1 (en) 2009-07-16
WO2009114040A3 (en) 2010-05-27
WO2009114040A2 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
NI201000042A (es) Anticuerpos anti-il-12/23p40, epitopes, formulaciones, composiciones, métodos y usos.
EA200870129A1 (ru) Человеческие антитела против il-23, композиции, способы и применение
UA118441C2 (uk) Антитіло, що розпізнає альфа-синуклеїн
ECSP077261A (es) Composición de anticuerpo her2
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
ECSP077888A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
CY1116302T1 (el) Συνθεση πεπτιδιων που σχετιζονται με ογκους και σχετικου αντικαρκινικου εμβολιου για τη θεραπεια του γλοιοβλαστωματος (glioblastoma, gbm) και αλλων μορφων καρκινου
MX2009005414A (es) Formulaciones liquidas de anticuerpo antirrabico.
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
CL2008003537A1 (es) Compuestos derivados de 2-amino-pirimidina, antagonistas de receptores h4; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad alergica, inmunologica o inflamatoria o dolor.
MY157772A (en) Antibody formulation
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
DK1896073T3 (da) Anti-il-antistoffer, sammensætninger, fremgangsmåder og anvendelser
EA201000424A1 (ru) Антитела к il-23
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
DK1784426T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
CR10561A (es) Vacunas para malaria
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA200702532A1 (ru) Антитела против мср-1, композиции, способы и применения
WO2007078879A3 (en) Lipopeptide compositions and methods of use thereof
UA117657C2 (uk) Антитіло до трансглютамінази 2 (tg2)
ITRM20040586A1 (it) Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
MX2010009640A (es) Uso de conjugados de interleucina-1 en el tratamiento de diabetes.
UA109148C2 (uk) Композиції на основі антитіла проти vegfr-3